Myelodysplastic Syndrome Clinical Trial
Official title:
Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies
Childhood leukemias which cannot be cured by chemotherapy alone may be effectively treated
by allogeneic bone marrow transplantation. Moreover, for patients with chronic myelogenous
leukemia (CML), allogeneic hematopoietic stem cell transplantation (HSCT) is the only proven
curative modality of treatment. Patients who have received hematopoietic stem cells from an
HLA matched sibling donor have proven to be less at risk for disease relapse and regimen
related toxicity. However, about 70% of patients in need of HSCT do not have an HLA matched
sibling donor. This necessitates the search for alternative donors, which may increase the
risk of a poor outcome.
The nature of the hematopoietic stem cell graft has been implicated as a primary factor
determining these outcomes. The standard stem cell graft has been unmanipulated bone marrow,
but recently several advantages of T-lymphocyte depleted bone marrow and mobilized
peripheral blood progenitor cells (PBPC) have been demonstrated. However, T-cell depletion
may increase the risk of infectious complications and leukemic recurrence while an
unmanipulated stem cell graft may increase the risk of graft vs. host disease (GVHD). A key
element in long range strategies in improving outcomes for patients undergoing matched
unrelated donor (MUD) HSCT is to provide the optimal graft.
The primary objective of this clinical trial is to estimate the incidence of acute GVHD in
pediatric patients with hematologic malignancies who receive HSCT with an unmanipulated
marrow graft. The results of this study can be used as the foundation for future trials
related to engineering unrelated donor graft.
Secondary outcome evaluations for this clinical study include the following:
- To estimate the overall survival in patients with high risk hematological malignancies
who receive a HSCT with an unmanipulated marrow graft or a peripheral blood stem cell
graft
- To estimate disease-free survival and relapse rates
- To estimate the rates of chronic GvHD and graft failure
- To estimate the incidence of non-hematologic peri-transplant regimen-related toxicity
and regimen-related mortality in the first 100 days after transplantation
- To estimate the time to neutrophil and platelet engraftment after transplantation
- To determine the degree of NK cell and T-cell immune reconstitution at 30 days and 100
days post-transplant
- To estimate the incidence of EBV reactivation or post-transplant lymphoproliferative
disease (PTLPD)
- To determine the pharmacokinetics of anti-thymocyte globulin (rATG) in patients
receiving allogeneic transplantation and the development of rATG antibodies
Originally this study began as a randomized comparison between unmanipulated bone marrow and
T-cell depleted bone marrow utilizing the investigational CliniMACS selection system. The
hypothesis to be tested at the time was that the incidence of severe acute GvHD was
significantly reduced in children who received HSCT with a T-cell depleted bone marrow stem
cell graft as compared to those receiving an unmanipulated graft. Approximately midway
through the study the evidence indicated that although the incidence of severe acute GvHD
with T-cell depletion was low, it was not significantly lower than the standard treatment of
unmanipulated bone marrow. Therefore the study was amended to remove the T-cell depleted arm
and continue accrual to one arm providing all patients with an unmanipulated bone marrow
stem cell graft. The primary objective then being to determine if the true incidence of
severe acute GvHD was below 15% as reported. The observational group receiving PBPC remained
open for those patients whose donors or donor centers chose to provide PBPC in lieu of bone
marrow. Only one such patient was assigned to this group; therefore, no valid conclusions
can be formulated.
Intervention analysis was based on those patients who received an unmanipulated stem cell
product only. For this study, the investigators had requested bone marrow for all study
subjects. However, the final determination of the source of the hematopoietic stem cells,
bone marrow or peripheral blood, was at the discretion of the donor and the donor center.
Those participants who received a peripheral blood stem cell product were followed in the
observational group only. All participants, whether recipients of a bone marrow or blood
stem cell product, received the same preparative conditioning regimen
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT01200355 -
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Completed |
NCT03941769 -
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
|
Phase 1/Phase 2 | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT00987480 -
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
|
Phase 2 | |
Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Completed |
NCT02756572 -
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
|
Phase 2 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Completed |
NCT02543879 -
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT02188290 -
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
|
N/A | |
Completed |
NCT02262312 -
Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome
|
Phase 0 | |
Recruiting |
NCT02330692 -
Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome
|
||
Completed |
NCT01684150 -
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
|
Phase 1 |